01 / issuers, in pricing order
8 priced offerings
Each record shows the SEC-assigned industry code and why the issuer sits in its sector, the filing timeline from first submission to the final prospectus, and the evidence signals found in the 424B4 text. Signal counts are phrase occurrences, not a quality score
Biotech and pharmaScribe Therapeutics, Inc.
Clinical-stage in vivo CRISPR genome-editing therapies
Classification basis SEC SIC 2836 (Biological Products, (No Diagnostic Substances)); prospectus business description read and consistent
- First submission
- Draft (DRS) 9 Jan 2026
- Public S-1
- 2 Jul 2026
- S-1/A amendments
- 2
- Priced (424B4)
- 27 Jul 2026
- Days, first submission to pricing
- 199
- Staff letters released
- not yet released
- Clinical evidencePhase 1 10Phase 2 3Phase 3 2Pivotal study 1Topline data 2Clinical hold 4
- Regulatory pathwayIND 21NDA or BLA 61Expedited designation 51
- Quality and manufacturingcGMP 17Contract manufacturer 27Form 483 or warning letter 1Recall 12
- Commercial operationsReimbursement 30Medicare or Medicaid 41Payer contracts 30Sales force 3
- Healthcare complianceHIPAA 2Anti-Kickback Statute 11
- Financial disclosureEmerging growth company 34Cash runway statement 1
Final prospectus (424B4) ↗First public S-1, 2 Jul 2026 ↗All filings, CIK 1853921 ↗
LSH-2026Q3-53921 · accession 0001193125-26-316503 · checked September 2026 · verified
Biotech and pharmaApnimed, Inc.
Late-stage oral therapies for obstructive sleep apnea and related breathing disorders
Classification basis SEC SIC 2834 (Pharmaceutical Preparations); prospectus business description read and consistent
- First submission
- Draft (DRS) 1 Jul 2024
- Public S-1
- 10 Jul 2026
- S-1/A amendments
- 1
- Priced (424B4)
- 31 Jul 2026
- Days, first submission to pricing
- 760
- Staff letters released
- not yet released
- Clinical evidencePhase 1 9Phase 2 10Phase 3 55Topline data 5Clinical hold 3
- Regulatory pathwayIND 28NDA or BLA 5Expedited designation 44
- Quality and manufacturingcGMP 19Contract manufacturer 52Form 483 or warning letter 8Recall 9
- Commercial operationsReimbursement 78Medicare or Medicaid 61Payer contracts 89Sales force 8
- Healthcare complianceHIPAA 16Anti-Kickback Statute 3
- Financial disclosureMaterial weakness identified 1Emerging growth company 27Cash runway statement 2Dual-class or controlled company 59
Final prospectus (424B4) ↗First public S-1, 10 Jul 2026 ↗All filings, CIK 1745648 ↗
LSH-2026Q3-45648 · accession 0001193125-26-328422 · checked September 2026 · verified
Biotech and pharmaAttovia Therapeutics, Inc.
Clinical-stage biotherapeutics for immune-mediated diseases
Classification basis SEC SIC 2836 (Biological Products, (No Diagnostic Substances)); prospectus business description read and consistent
- First submission
- Draft (DRS) 19 Dec 2025
- Public S-1
- 14 Jul 2026
- S-1/A amendments
- 2
- Priced (424B4)
- 5 Aug 2026
- Days, first submission to pricing
- 229
- Staff letters released
- not yet released
- Clinical evidencePhase 1 48Phase 2 15Phase 3 12Topline data 4Clinical hold 7Clinical validation 1
- Regulatory pathwayIND 35NDA or BLA 47Expedited designation 9
- Quality and manufacturingcGMP 16Contract manufacturer 36Form 483 or warning letter 4Recall 7
- Commercial operationsReimbursement 66Medicare or Medicaid 54Payer contracts 45Sales force 3
- Healthcare complianceHIPAA 11Anti-Kickback Statute 10
- Financial disclosureEmerging growth company 26
Final prospectus (424B4) ↗First public S-1, 14 Jul 2026 ↗All filings, CIK 2058707 ↗
LSH-2026Q3-58707 · accession 0001193125-26-334997 · checked September 2026 · verified
Biotech and pharmaBraveheart Bio, Inc.
Clinical-stage therapies for hypertrophic cardiomyopathy
Classification basis SEC SIC 2834 (Pharmaceutical Preparations); prospectus business description read and consistent
- First submission
- Draft (DRS) 29 Apr 2026
- Public S-1
- 15 Jul 2026
- S-1/A amendments
- 1
- Priced (424B4)
- 6 Aug 2026
- Days, first submission to pricing
- 99
- Staff letters released
- not yet released
- Clinical evidencePhase 1 20Phase 2 77Phase 3 110Pivotal study 7Topline data 3Clinical hold 9Clinical validation 1
- Regulatory pathwayIND 35NDA or BLA 7Expedited designation 58
- Quality and manufacturingcGMP 20Contract manufacturer 18Form 483 or warning letter 5Recall 10
- Commercial operationsReimbursement 68Medicare or Medicaid 49Payer contracts 45Sales force 4
- Healthcare complianceHIPAA 5Anti-Kickback Statute 6
- Financial disclosureEmerging growth company 31Cash runway statement 2
Final prospectus (424B4) ↗First public S-1, 15 Jul 2026 ↗All filings, CIK 2131524 ↗
LSH-2026Q3-31524 · accession 0001628280-26-054354 · checked September 2026 · verified
Biotech and pharmaBlossomHill Therapeutics, Inc.
Clinical-stage small-molecule cancer therapeutics
Classification basis SEC SIC 2834 (Pharmaceutical Preparations); prospectus business description read and consistent
- First submission
- Draft (DRS) 24 Apr 2026
- Public S-1
- 17 Jul 2026
- S-1/A amendments
- 1
- Priced (424B4)
- 7 Aug 2026
- Days, first submission to pricing
- 105
- Staff letters released
- not yet released
- Clinical evidencePhase 1 63Phase 2 23Phase 3 6Pivotal study 1Topline data 1Clinical hold 4Clinical validation 2
- Regulatory pathwayIND 45NDA or BLA 7Expedited designation 38PMA or De Novo 1
- Quality and manufacturingcGMP 20Contract manufacturer 11Form 483 or warning letter 4Recall 7
- Commercial operationsReimbursement 62Medicare or Medicaid 57Payer contracts 46Sales force 5
- Healthcare complianceHIPAA 9Anti-Kickback Statute 13
- Financial disclosureAuditor going-concern paragraph 3Emerging growth company 39
Final prospectus (424B4) ↗First public S-1, 17 Jul 2026 ↗All filings, CIK 1839970 ↗
LSH-2026Q3-39970 · accession 0001193125-26-340215 · checked September 2026 · verified
Biotech and pharmaLatigo Biotherapeutics, Inc.
Clinical-stage non-opioid pain medicines
Classification basis SEC SIC 2834 (Pharmaceutical Preparations); prospectus business description read and consistent
- First submission
- Draft (DRS) 27 Mar 2026
- Public S-1
- 17 Jul 2026
- S-1/A amendments
- 2
- Priced (424B4)
- 7 Aug 2026
- Days, first submission to pricing
- 133
- Staff letters released
- not yet released
- Clinical evidencePhase 1 33Phase 2 28Phase 3 39Pivotal study 9Topline data 16Clinical hold 7Clinical validation 2
- Regulatory pathwayIND 22NDA or BLA 8Expedited designation 23
- Quality and manufacturingcGMP 20Contract manufacturer 18Form 483 or warning letter 5Recall 8
- Commercial operationsReimbursement 60CPT or HCPCS coding 39Medicare or Medicaid 56Payer contracts 50Sales force 7
- Healthcare complianceHIPAA 10Anti-Kickback Statute 13
- Financial disclosureAuditor going-concern paragraph 4Material weakness identified 3Emerging growth company 33
Final prospectus (424B4) ↗First public S-1, 17 Jul 2026 ↗All filings, CIK 2056611 ↗
LSH-2026Q3-56611 · accession 0001193125-26-340329 · checked September 2026 · verified
Biotech and pharmaVogenx, Inc.
Clinical-stage therapies for metabolic disorders, including post-bariatric hypoglycemia
Classification basis SEC SIC 2834 (Pharmaceutical Preparations); prospectus business description read and consistent
- First submission
- Draft (DRS) 20 Feb 2026
- Public S-1
- 15 Jul 2026
- S-1/A amendments
- 2
- Priced (424B4)
- 12 Aug 2026
- Days, first submission to pricing
- 173
- Staff letters released
- not yet released
- Clinical evidencePhase 1 12Phase 2 32Phase 3 10Pivotal study 2Topline data 2Clinical hold 14
- Regulatory pathwayIND 34NDA or BLA 9Expedited designation 43
- Quality and manufacturingcGMP 19Contract manufacturer 19Form 483 or warning letter 2Recall 6
- Commercial operationsReimbursement 98Medicare or Medicaid 45Payer contracts 61Sales force 5
- Healthcare complianceHIPAA 8Anti-Kickback Statute 5
- Financial disclosureAuditor going-concern paragraph 1Material weakness identified 2Emerging growth company 31Cash runway statement 2
Final prospectus (424B4) ↗First public S-1, 15 Jul 2026 ↗All filings, CIK 1903784 ↗
LSH-2026Q3-03784 · accession 0001185185-26-003448 · checked September 2026 · verified
Biotech and pharmaElectra Therapeutics, Inc.
Late clinical-stage precision medicines for immune-mediated diseases and cancer
Classification basis SEC SIC 2836 (Biological Products, (No Diagnostic Substances)); prospectus business description read and consistent
- First submission
- Draft (DRS) 26 Jun 2026
- Public S-1
- 28 Aug 2026
- S-1/A amendments
- 1
- Priced (424B4)
- 18 Sep 2026
- Days, first submission to pricing
- 84
- Staff letters released
- not yet released
- Clinical evidencePhase 1 37Phase 2 2Phase 3 3Topline data 6Clinical hold 5Clinical validation 2
- Regulatory pathwayIND 28NDA or BLA 74Expedited designation 62
- Quality and manufacturingcGMP 22Contract manufacturer 45Form 483 or warning letter 4Recall 8
- Commercial operationsReimbursement 74Medicare or Medicaid 51Payer contracts 49Sales force 3
- Healthcare complianceHIPAA 13Anti-Kickback Statute 10
- Financial disclosureAuditor going-concern paragraph 4Emerging growth company 31Cash runway statement 2
Final prospectus (424B4) ↗First public S-1, 28 Aug 2026 ↗All filings, CIK 2088082 ↗
LSH-2026Q3-88082 · accession 0001193125-26-395670 · checked September 2026 · verified